SBC News Voice of the Sports Betting Industry
Flutter Entertainment has been announced as the headline partner of Cure Leukaemia’s flagship cycling event, The Tour 21.
The agreement covers the 2023, 2024 and 2025 iterations of the £1m fundraising event, which sees a team of 20 amateur cyclists aiming to complete all 21 stages, over 3,000km, of the Tour de France.
Kerry McNally, Flutter Head of Communities, noted: “We’re delighted to be working with Cure Leukaemia and supporting The Tour 21. It is an exciting partnership that brings together our passion for sport with our commitment to Do More to support the communities in which we operate.
“Cure Leukaemia is undertaking transformational trials to help treat blood cancer patients around the world and we could not be prouder to play a role in helping them to eradicate this devastating illness.”
The 2023 edition takes place from 24 June – one week ahead of the Tour De France – starting in Bilbao, before finishing in central Paris on 16 July.
Funds raised from the race are invested into the Trials Acceleration Programme (TAP) network, which covers a catchment area of over 20 million people to provide access to potentially life-saving treatments not available through standard care, the pair detailed.
The operator has highlighted the importance of the event, explaining that a funding of over £1m is required each year in order to facilitate treatments for blood cancer.
“I am extremely proud that Flutter has agreed to partner with The Tour 21,” added James McLaughlin, Cure Leukaemia Chief Executive. “Their mission and strategy perfectly aligns with Cure Leukaemia’s ultimate ambition to eradicate blood cancer.
“Flutter as the headline partner of the event takes The Tour 21 to a whole new level, working alongside our strategic partnerships with A.S.O, Santini, Ribble and NBC Sports to further raise the profile of the event and the charity to attract further sponsors and corporate engagement.”
The Executive also highlighted the significant difference to the event’s fundraising total that the pair will make, as well the global impact of clinical trials and treating blood cancer patients.
